Transcriptional Selectivity of Epigenetic Therapy in Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
A central challenge in the development of epigenetic cancer therapy is the ability to direct selectivity in modulating gene expression for disease-selective efficacy. To address this issue, we characterized by RNA-seq, DNA methylation, and ChIP-seq analyses the epigenetic response of a set of colon, breast, and leukemia cancer cell lines to small-molecule inhibitors against DNA methyltransferases (DAC), histone deacetylases (Depsi), histone demethylases (KDM1A inhibitor S2101), and histone methylases (EHMT2 inhibitor UNC0638 and EZH2 inhibitor GSK343). We also characterized the effects of DAC as combined with the other compounds. Averaged over the cancer cell models used, we found that DAC affected 8.6% of the transcriptome and that 95.4% of the genes affected were upregulated. DAC preferentially regulated genes that were silenced in cancer and that were methylated at their promoters. In contrast, Depsi affected the expression of 30.4% of the transcriptome but showed little selectivity for gene upregulation or silenced genes. S2101, UNC0638, and GSK343 affected only 2% of the transcriptome, with UNC0638 and GSK343 preferentially targeting genes marked with H3K9me2 or H3K27me3, respectively. When combined with histone methylase inhibitors, the extent of gene upregulation by DAC was extended while still maintaining selectivity for DNA-methylated genes and silenced genes. However, the genes upregulated by combination treatment exhibited limited overlap, indicating the possibility of targeting distinct sets of genes based on different epigenetic therapy combinations. Overall, our results demonstrated that DNA methyltransferase inhibitors preferentially target cancer-relevant genes and can be combined with inhibitors targeting histone methylation for synergistic effects while still maintaining selectivity. Cancer Res; 77(2); 470–81. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 2×
“3 Introduction Cancers often display aberrant epigenetic modifications in DNA methylation or histone modifications, which can lead to silencing of critical tumor suppressor genes (1).”
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 7×
“These include inhibitors for KDM1A (22,23), a histone demethylase that catalyzes removal of H3K4 mono and di methylation, EHMT2 (24,25), a histone methyltransferase that catalyzes mono and di methylation of H3K9, and EZH2 (26-29), a histone methyltransferase that catalyzes mono, di, and tri methylation of H3K27.”
InfluentialNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 2×
“initial response to epigenetic therapy (4,13,14), and patients with solid tumors have limited”
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“In addition to DNMT inhibitors, the histone deacetylase (HDAC) inhibitors vorinostat (SAHA) and romidepsin (depsipeptide) have been approved by the FDA for the treatment of cutaneous T-cell lymphoma (10,11).”
Epigenetic cancer therapy: rationales, targets and drugs
Rius, M., & Lyko, F. (2012) · Oncogene · doi:10.1038/onc.2011.601 · Cited by 157 · cited 1×
“Despite these successes, epigenetic therapy still faces major questions about the selectivity of gene reactivation (12), since the drugs affects enzymes involved in day to day cellular regulation.”
Cited by
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 287
Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
Liu, M., Thomas, S. L., DeWitt, A. K., Zhou, W., Madaj, Z. B., Ohtani, H., Baylin, S. B., Liang, G., & Jones, P. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3953 · Cited by 127
“This combination has also been shown to effectively increase the expression of immune genes in a colon cell line (39).”
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
Metadata
- Authors
- Sato, T., Cesaroni, M., Chung, W., Panjarian, S., Tran, A., Madzo, J., Okamoto, Y., Zhang, H., Chen, X., Jelinek, J., & Issa, J.-P. J.
- Venue
- Cancer Research
- Published
- 2017-01-15
- Volume
- 77
- Issue
- 2
- Pages
- 470-481
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2555974126
- Cited by
- 64
- References
- 6
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcriptional Selectivity of Epigenetic Therapy in Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0834
- The paper
- Sato, T., Cesaroni, M., Chung, W., Panjarian, S., Tran, A., Madzo, J., Okamoto, Y., Zhang, H., Chen, X., Jelinek, J., & Issa, J.-P. J. (2017). Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.